Tesamorelin
$79.99
Tesamorelin
GHRH analog with visceral-fat evidence
Identity: modified 44-amino-acid peptide that stimulates GH release.
Approved Egrifta use: excess abdominal fat in HIV-associated
lipodystrophy.
Visceral fat surrounds organs; subcutaneous fat lies beneath the skin.
Description
Tesamorelin – 10MG
Pathway: GHRH-receptor activation -> pituitary GH release -> IGF-1.
Human finding: trials measured reduced visceral fat in the studied HIV
population.
Outcome distinction: visceral-fat reduction differs from total-body weight
loss.
Interactions: GH effects can alter glucocorticoid activation and some
drug-clearance pathways.
Side effects: fluid retention, elevated IGF-1, glucose intolerance and allergy.
Contraindications include active malignancy, pregnancy and specified
pituitary-axis disorders.
Reviews
There are no reviews yet.